The battle against fatty liver disease reveals a clear winner among competing drug approaches, with implications for millions facing this silent epidemic. As metabolic dysfunction-associated steatohepatitis becomes increasingly common alongside diabetes and obesity, identifying the most effective therapeutic strategies could reshape treatment paradigms for liver health and metabolic wellness.
This comprehensive network meta-analysis spanning 64 clinical trials and nearly 13,000 participants demonstrates that drugs targeting metabolic dysfunction and insulin sensitivity consistently outperform other approaches. Treatments focusing on these pathways achieved odds ratios between 2.5 and 7.1 compared to placebo, with fibroblast growth factor 21 analogs and incretin-based multi-receptor agonists emerging as top performers. In contrast, anti-inflammatory and anti-fibrotic agents showed inconsistent results across liver biopsy measurements, suggesting that addressing root metabolic causes proves more effective than targeting downstream inflammation or scarring processes.
This finding aligns with growing recognition that fatty liver disease represents a hepatic manifestation of broader metabolic dysregulation rather than an isolated liver condition. The superior performance of metabolic-targeting therapies validates treating the systemic insulin resistance and metabolic dysfunction that drive liver fat accumulation. However, even leading treatments left 35-70% of patients without meaningful biopsy improvements, highlighting the complexity of reversing established liver damage. The substantial placebo response rates of 11-18% also underscore the importance of lifestyle modifications alongside pharmaceutical interventions. These results suggest that future therapeutic success may require combination approaches targeting multiple pathways simultaneously, while emphasizing early intervention before irreversible fibrotic changes occur.